U.S. Markets closed

(SNTA)

. Currency in USD
Add to watchlist
People also watch
THLDINFISNSSGALEZGNX
Full screen
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Madrigal Pharmaceuticals Inc (MDGL) A Good Stock to Buy?
    Insider Monkey8 months ago

    Is Madrigal Pharmaceuticals Inc (MDGL) A Good Stock to Buy?

    Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Synta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus
    Zackslast year

    Synta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus

    Synta (SNTA) reported a second-quarter 2016 loss of 2 cents per share, much lower than the year-ago loss of 15 cents.

  • Zacks Small Cap Researchlast year

    VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for Hypercholersterolemia to Commence in mid-2016

    Viking’s (VKTX) lead drug candidate is VK5211, a third-generation non-steroidal Selective Androgen Receptor Modulator (SARM) that is being developed for maintenance or improvement of lean body mass (LBM), bone mineral density (BMD), and function in patients recovering from non-elective hip fracture surgery. Hip fracture is associated with a number of morbidities, the majority of which are the result of deleterious changes in body composition following the injury.